CA-VELO3D
19.4.2021 15:06:07 CEST | Business Wire | Press release
VELO3D Inc ., a leader in additive manufacturing (AM) for high-value metal parts, today announced the appointment of renowned business leader Stefan Krause to the company’s board of directors as audit committee chair.
With more than 30 years of experience working at some of the most recognizable and successful companies in the world, Krause has built a singular career that previously included a chief financial officer (CFO) role at BMW – where he was the youngest ever to hold the position and a member of the management board. Krause then took on a similar role at Deutsche Bank, earning himself a reputation as one of the world’s top CFOs. He also previously served as chairman of Rolls Royce Motorcars, Postbank AG and BHF Bank. He has been in the supervisory boards of Rocket Internet and Allianz AG.
Krause has also been involved with multiple startups during his career and has been CEO and co-founder of electric vehicle maker Canoo.
“Stefan’s international business background, his expertise in branding and go-to-market strategy and his deep experience managing public companies make him a welcome and valuable addition to our board as VELO3D prepares for life as a public company,” said Benny Buller, founder and CEO, VELO3D . “His presence will help VELO3D continue our accelerated growth at scale and speed adoption of our full-stack metal AM solution, freeing the most imaginative engineers on the planet to build the impossible.”
Last month VELO3D announced plans to merge with JAWS Spitfire Acquisition Corporation (NYSE: SPFR) and become a public company.
The company also previously announced a U.S.-wide distribution partnership with GoEngineer, and has said it plans to expand commercial operations in Europe, while establishing strategic partnerships in both Europe and Asia, demonstrating the company’s focus on supporting visionary aviation, energy, space and industrial customers all over the world. Current customers include Chromalloy, Honeywell, Lam Research, and Primus Aerospace.
“With truly unique capabilities setting it apart from others in the AM space, VELO3D is actually delivering on 3D printing’s previously unfulfilled promise of innovation and design freedom,” said Krause. “This is due to a relentless focus on pushing the limits of manufacturing technology and helping customers design and build the parts they need without compromise. I’m looking forward to working with Benny and the team to help companies become more agile and innovate faster.”
Earlier this year VELO3D was named to Fast Company ’s 2021 list of the world’s most innovative companies , among the top ranked in the manufacturing category for their profound impact on the 3D printing industry.
To learn more about how VELO3D empowers engineers and designers to imagine more, and additively manufacture nearly anything, follow VELO3D on LinkedIn or visit Velo3D.com .
About VELO3D
VELO3D empowers companies to imagine more and additively manufacture nearly anything. Bringing together an integrated, end-to-end solution of software, hardware, and process-control innovation, VELO3D’ s technology for 3D metal printing delivers unparalleled quality control for serial production and enhanced part performance. With VELO3D Flow™ print preparation software, Sapphire® laser powder bed AM system and Assure™ quality assurance software, manufacturers can accelerate product innovation, become more agile and responsive to market needs and reduce costs. First in the industry to introduce SupportFree metal 3D printing, which allows for the manufacture of previously impossible geometries, the company is based in Silicon Valley and is privately funded. VELO3D was named to Fast Company’s prestigious annual list of the World’s Most Innovative Companies for 2021. For more information, follow on LinkedIn or visit Velo3D.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210419005527/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom